- Advaxis Inc ADXS has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.
- The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
- The Phase 1 open-label dose-escalation study will evaluate the safety and tolerability of two dose levels of ADXS-504 monotherapy.
- The study will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.
- Recently, the Company has announced a reverse merger agreement with privately-held Biosight Ltd.
- Price Action: ADXS shares are up 3.7% at $0.45 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
